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Abstract: This review addresses the role of adjunctive tetracycline therapy in the management of periodontal diseases and 
its efficacy in reducing inflammatory burden, oxidative stress and its sequelae in patients with coexisting features of 
metabolic syndrome. Removal of the dimethylamine group at C4 of the tetracycline molecule reduces its antibiotic prop-
erties, enhancing its non-antimicrobial actions; this strategy has aided the development of several chemically modified tet-
racyclines such as minocycline and doxycycline, by altering different regions of the molecule for focused action on bio-
logical targets. Tetracyclines are effective in reducing inflammation by inhibiting matrix metalloproteinases, preventing 
excessive angiogenesis, inhibiting apoptosis and stimulating bone formation. There are important applications for tetracy-
clines in the management of diabetic, dyslipidaemic periodontal patients who smoke. The diverse mechanisms of action of 
tetracyclines in overcoming oxidative stress and enhancing matrix synthesis are discussed in this review.  
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INTRODUCTION 
  There is increasing awareness of the role of oxidative 
stress in causing significant damage to hard and soft tissues. 
The relevance of oxidative stress induced tissue damage as a 
common nucleus of disease progression in periodontal and 
metabolic diseases is highlighted in this review. A therapeu-
tic role for the non-antimicrobial actions of tetracyclines is 
discussed in this context. 
  Periodontal disease has a microbial aetiology and an in-
flammatory pathogenesis, characterised by destruction of 
tooth-supporting soft and hard tissues of the alveolus result-
ing in periodontal pockets and roots denuded of periodontal 
ligament, cementum and alveolar bone. Periodontal patients 
have been reported to have a higher prevalence of systemic 
diseases than a general dental population and are more likely 
to be on medication for multiple ailments [1] Modulation of 
systemic diseases such as diabetes, also associated with a 
substantial inflammatory burden could affect the progression 
of periodontal disease [2-4]. Prolonged hyperglycaemic 
spells are likely to be a contributory factor, considering the 
frequency and severity of periodontal disease in those with 
poor glycaemic control [5]. Specific periodontal pathogens 
and their products associated with host virulence can con-
tribute to a significant systemic inflammatory burden [6-8]. 
Smokers are more at risk of developing severe periodontal 
disease than non-smokers [9, 10]. It is relevant that uncon-
trolled diabetes mellitus is associated with more severe de-
structive periodontal disease, worse in smokers [11]. 
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  Effective management of severe periodontal disease can 
reduce the inflammatory burden in this population of pa-
tients. This has been demonstrated with regard to reduced 
insulin resistance in diabetic patients following effective 
periodontal management [12]. Raised levels of C- reactive 
proteins (CRP) amongst periodontal patients and those with 
acute myocardial infarction has been reported, independent 
of other risk factors [13]. Three months after intensive perio-
dontal treatment in patients with a proven history of cardio-
vascular disease there was significant reduction in levels of 
CRP and oxidised low density lipoprotein [14]; associated 
host responses contribute to the manifestations of clinical 
parameters of periodontal disease [15]. The link between 
cardiovascular and periodontal diseases is well documented 
while a causal relationship is more difficult to establish. A 
generalised distribution of severe periodontal disease is 
likely to contribute to significant inflammatory loading in 
subjects with systemic chronic inflammatory diseases. There 
is potential for adjunctive therapeutic management of perio-
dontal diseases with the tetracycline group of drugs and 
other host modulatory agents used to arrest an over exuber-
ant inflammatory response [16]. They have beneficial effects 
on systemic diseases which are also driven by oxidative stress; 
in view of their antioxidant, anti-inflammatory and proanabo-
lic effects [17] in addition to their anti-microbial actions.  
  These non-antibiotic properties of tetracyclines also in-
clude immunomodulatory, angiogenic and anti-apoptotic 
effects. There are 3 main groups of tetracyclines consisting 
of the natural product, semi-synthetic compounds and the 
chemically modified tetracyclines [18]. The tetracyclines 
have a chemical structure consisting of a tetracyclic naph-
thacene carboxamide ring system. The dimethylamine group 
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the drug and its removal has the advantage of reducing these 
effects and also enhancing its non-antibiotic actions [18]. 
This is used to advantage in several other applications of 
such chemically modified tetracyclines. Biological targets of 
action of tetracyclines can be enhanced by modifying ring D 
through carbon locations C7-C9. This is the basis of efficacy 
of the semisynthetic compounds minocycline and doxycy-
cline. Their anti-inflammatory effects are initiated by several 
mechanisms. They inhibit matrix metalloproteinases (MMPs). 
MMPs are zinc-dependent endopeptidases which play an 
important role in remodelling of connective tissue matrices 
in wound healing and rheumatoid arthritis. 
APPLICATIONS FOR ADJUNCTIVE USE OF TET-
RACYCLINES AS ANTIMICROBIALS IN THE MAN-
AGEMENT OF PERIODONTAL DISEASES 
  The initiation and progression of periodontal diseases are 
dependent on bacterial plaque. Treatment strategy is based 
on controlling pathogenic potential to sub-threshold levels 
for disease production. This is achieved predominantly by 
carrying out thorough periodontal root surface debridement. 
Adjunctive antimicrobials have been used over the past 20 
years in the management of periodontal diseases. They are 
particularly useful in the management of aggressive forms 
that present with severe disease for age in susceptible indi-
viduals [19, 20]. Other indications are recalcitrant sites 
common in smokers [21, 22] which may not have responded 
to conventional root surface debridement and also in the 
management of acute periodontal conditions. It is often a 
matter of clinical judgement with regard to choosing the best 
treatment option for a particular mode of disease presenta-
tion.  
  A systematic review comprising a meta-analysis of 19 
studies showed that combining root surface debridement 
with sustained release antimicrobials was significantly more 
effective in resolving periodontal disease than root surface 
debridement alone [23]. Minocycline gel, microencapsulated 
minocycline, chlorhexidine chip and doxycycline gel were 
sustained delivery systems used for placement in the perio-
dontal pocket. It was also shown that the effect of antimicro-
bial agents alone was comparable to that of root surface de-
bridement alone. It must be emphasised that judicious use of 
antimicrobials is essential. They are best reserved for at risk 
young populations, those compromised with systemic dis-
eases which accelerate periodontal disease progression, those 
who have not responded to conventional measures and those 
presenting with acute periodontal conditions; for adjunctive 
use and not as a substitute for root surface debridement, 
compatible with current standards of care.  
  Other workers reinforce this view. Periodontal root sur-
face debridement with adjunctive application of minocycline 
microspheres in periodontal pockets has been shown to con-
sistently reduce parameters of site based periodontal disease 
compared with root surface debridement alone in a multicen-
tre randomised trial of 499 patients [24]. Similar results have 
been reported in a split mouth study of 15 patients over 18 
weeks with significant improvement in periodontal para-
menters and IL-1 content, when root surface debridement 
was combined with adjunctive application of minocycline 
[25]. Minocycline hydrochloride microspheres have also 
been shown to be effective against peri-implantitis [26]; 
there was a significant reduction in the periodontal patho-
genic load, particularly of Aggregatibacter actinomycetem-
comitans over a period of one year. In view of microbial 
resistance caused by excessive use of antimicrobials one 
would need to consider the efficacy of thorough mechanical 
root surface debridement in reducing microbial loading to 
sub-threshold levels for disease production; and utilise the 
non-antimicrobial formulations of tetracyclines as adjuncts 
for their actions detailed in the sections that follow.  
  Long-term usage of antimicrobial formulations of tetra-
cyclines in current and past users could contribute to hepato-
toxicity. Doxycycline is potentially less hepatotoxic than 
tetracycline and could be a safer substitute where appropriate 
[27]. Their applications as adjuncts to periodontal manage-
ment are relatively short term and less likely to induce toxic-
ity or microbial resistance, in comparison with those for 
chronic conditions such as acne and rosacea. Stringent sur-
veillance and selective usage limited to cases that require this 
intervention must be practised in order to minimise the de-
velopment of microbial resistance. An In vitro study was 
done to investigate the effects of minocycline and doxycy-
cline on human gingival fibroblasts, epithelial cells and 
periodontal ligament fibroblasts with regard to cell survival 
and protein expression genes [28]. The concentrations used 
were greater than minimum inhibitory concentrations for 
90% of periodontal pathogens and the results showed little or 
no effect on the cells for the parameters studied. This implies 
minimal cellular damage with topical application of these 
antibiotics; although, further work needs to be done before 
these findings can be extrapolated to in vivo conditions.  
  The tetracyclines are particularly versatile in their ability 
to combat oxidative stress, mop up free radicals and inhibit 
an excessive inflammatory response secondary to an anti-
genic stimulus [29]. These features of inflammation charac-
terise some of the more aggressive forms of early onset 
periodontal diseases. The actions of tetracyclines mentioned 
above have been utilised in the evolution of non-
antimicrobial chemically modified tetracyclines (CMTs) and 
low dose doxycycline, with the specific aim of curtailing the 
damaging effects of an over-exuberant inflammatory re-
sponse seen in certain categories of periodontal diseases, 
often compounded by poorly controlled diabetes mellitus 
and cardiovascular disease. In the management of these cases 
presenting with periodontal disease the emphasis would be 
on thorough root surface debridement to reduce the micro-
bial presence to sub-pathogenic levels and the adjunctive use 
of non-antimicrobial tetracyclines / low dose doxycycline 
formulations to modulate an excessive host response that can 
be damaging. Some of the positive clinical outcomes when 
using these formulations for the adjunctive management of 
periodontal patients, are due to the non-antimicrobial anti-
inflammatory actions of this group of drugs in an over-
exuberant inflammatory milieu that is damaging rather than 
protective.  
APPLICATIONS FOR NON-ANTIMICROBIAL AC-
TIONS OF TETRACYCLINES IN PERIODONTAL 
DISEASES AND DIABETES MELLITUS (DM)  
  Oxidative stress is a unifying mechanism for production 
of reactive oxygen species and plays a significant role in the 
manifestation of insulin resistance, atherogenic dyslipidae-
mia [30] and periodontal disease [4]. The term metabolic 
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metabolic origin for cardiovascular disease and type 2 diabe-
tes. These include hyperglycaemia, hypertension, dyslipi-
daemia and a pro-inflammatory state often associated with 
obesity [31]. It is relevant that patients with metabolic syn-
drome show significant correlation with the prevalence of 
severe periodontal disease initiated by pathogenic bacterial 
plaque. This is associated with high levels of inflammatory 
cytokines, other markers of inflammation and oxidative 
stress such as C-reactive proteins and low density lipopro-
teins, on par with metabolic diseases [32]. Periodontal pa-
tients with co-existing features of metabolic syndrome con-
stitute a good model for therapeutic interventions which re-
sult in improved metabolic control of their systemic diseases 
[33]. The non-antimicrobial anti-inflammatory actions of 
tetracyclines have useful applications in the management of 
inflammatory diseases as detailed below. 
  Early in the course of diabetes mellitus (DM), mRNAs 
for IL-1, TNF- and other pro-inflammatory mediators are 
increased in the retina, partly from activated microglia. Mi-
nocycline inhibits diabetes-induced cytokine and cytotoxin 
production and holds promise in preventing retinal complica-
tions of DM [34]. Bacterial LPS also causes marked upregu-
lation and release of IL-1, TNF- and NO in retinal micro-
glia; this was inhibited by minocycline which has significant 
impact in reducing the expression and release of these me-
diators [35]. Recent investigations [36] have demonstrated 
that doxycycline was more effective in inhibiting matrix 
metallo proteinases (MMPs) in human aortic smooth muscle 
cells than minocycline, by upregulating the MMP inhibitor 
TIMP-1 (Tissue inhibitor of metallo proteinase-1). These 
findings have implications on periodontal diseases initiated 
by lipopolysaccharide mediated inflammatory burden with 
applications for the MMP inhibitory actions of tetracyclines.  
  Doxycycline hyclate has been shown to accelerate perio-
dontal wound healing in diabetic mice [37] and humans [38]. 
Similar studies with Arestin (minocycline microspheres) 
have shown reduction in HbA1c and improved periodontal 
disease control over root debridement alone [39]. Adjunctive 
locally delivered doxycycline in periodontal pockets of 
smokers has been shown to be more effective than pocket 
debridement alone [40] in reducing the parameters of in-
flammatory periodontal disease. A combination of alendro-
nate and low dose doxycycline has demonstrated improved 
bone remodelling and decreased rate of progression of ex-
perimental periodontits in rats [41]. Both minocycline and 
doxycycline cause significant stimulation of osteoblastic 
cells at levels conventionally detected in plasma and gingival 
crevicular fluid; long term exposure of these cells to tetracy-
clines resulted in a proportional increase in mineralised bone 
matrix; while exposure to higher levels of these drugs re-
sulted in delayed cell proliferation and differentiation [42]. 
The above studies have implications on healing responses 
using adjunctive teracyclines in the management of perio-
dontal diseases in diabetic patients who smoke. This can 
overcome damaging effects of the oxidative stress imposed.  
Oxidative Stress Induced Sequelae of Diabetes, Dislipi-
daemia and Cardiovascular Disease: Context of Thera-
peutic Intervention with Tetracyclines as Antioxidants 
  Inflammatory burden from periodontal disease could 
compound the complications of diabetes mellitus and car-
diovascular disease in a systemically compromised popula-
tion. Fluctuating post-prandial glucose levels associated with 
higher levels of cytokines during hyperglycaemic spikes, 
contribute to oxidative stress induced damage more so than 
chronically elevated levels [43, 44]. A nutritional overload 
resulting in excessive amounts of glucose and fatty acids 
leads to ROS production. Interactions between glucose and 
plasma proteins result in the formation of advanced glycation 
end products (AGE) which in turn initiate the production of 
TNF-, IL-6, IL-18 and ROS; this contributes to chemical 
modification of lipoproteins and atherogenesis [45]. Admini-
stration of the antioxidant glutathione completely suppressed 
elevation of cytokines in response to glucose pulses. This 
implies that an oxidative stress induced mechanism is re-
sponsible for the inflammatory burden imposed by hypergly-
caemia in humans [46] with implications on atherosclerosis 
and cardiovascular disease. The oxidative stress induced 
pathogenesis of periodontal diseases is not dissimilar and has 
applications for the adjunctive use of tetracyclines as anti-
oxidants [47, 48] in the management of systemically com-
promised periodontal patients.  
  The above correlations seen in metabolic syndrome are 
often linked to obesity which has reached pandemic propor-
tions. Abdominal or visceral fat associated with waist cir-
cumference has a stronger correlation as a risk factor than 
peripheral fat [49, 50]. The combination of cigarette smoking 
and metabolic syndrome is particularly damaging. Smoking 
cessation should be emphasised for all patients with diabetes, 
cardiovascular disease and periodontal diseases. The UK 
guidelines on smoking cessation suggest a specific plan that 
incorporates a holistic approach to integrate educational, 
behavioural and pharmacological components to aid cessa-
tion and prevent relapse [51].  
  The pathophysiology of diabetes mellitus and cardiovas-
cular disease discussed above has implications on the pro-
gression of periodontal diseases. These risk criteria for oxi-
dative stress induced tissue damage have a logical place in 
the context of progressive loss of periodontal support for 
teeth. The relationship between periodontitis and diabetes is 
reciprocal [52, 53], for example AGE related cytokine spikes 
are of relevance in the pathogenesis of periodontal diseases 
and vice versa considering the importance of an inflamma-
tory burden, oxidative stress and its sequelae for the progres-
sion of both disease entities.  
SPECIFIC ANTI - INFLAMMATORY AND ANTI -
ANGIOGENIC TARGETS OF TETRACYCLINES  
  The collagenase MMPs that breakdown collagen are 
MMP-1, 8 and13 and those that affect basement membrane 
collagen (collagen IV) are the gelatinases known as MMPs 2 
and 9. Tetracycline and its analogues inhibit these enzyme 
systems [54].  
  Angiogenesis is facilitated by matrix degrading enzymes 
such as MMPs.  
  Minocycline and doxycycline have been shown to inhibit 
angiogenesis by preventing endothelial growth and activity 
of collagenase [55]. Inhibition of synthesis of MMP-8 and 
MMP-9 by endothelial cells in response to doxycycline and 
to a lesser extent by the chemically modified tetracyclines 
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These effects of tetracyclines have therapeutic implications 
on inflammatory processes associated with vascular tissue 
development. 
  Elastin degradation and MMP activity are reduced by 
doxycycline in a model representing aneurismal disease [57]. 
In a cell culture model of corneal epithelial cells treated with 
lipopolysaccharide, doxycycline inhibited the degree of for-
mation of IL-1 to an extent that was similar to that of corti-
costeroids [58]. It also prevents endotoxemia in vivo [59]. 
Doxycycline can cause dose dependent reduction in the pro-
duction of the cytokines IL-1, IL-6, TNF- and IFN- [60]. 
  Matrix metallo proteinases mediate different physiologi-
cal processes by digesting extracellular matrix components. 
The pathogenesis of several diseases is characterised by 
over-expression of MMPs. The activity of MMPs is regu-
lated by tissue inhibitors of MMPs (TIMPs) found in bone 
and other cells. Their biosynthesis is regulated by local and 
systemic hormones, uptake and degradation by cells. Con-
sidering their actions, abnormal expression of MMPs may 
lead to pathological conditions affecting bone and cartilage. 
Pharmacological agents that function as inhibitors of matrix 
metalloproteinases have useful therapeutic potential [61]. 
THERAPEUTIC ADVANTAGES OF MATRIX MET-
ALLO PROTEINASE INHIBITION 
  Subantimicrobial dosing with doxycycline (SDD; 20mg 
bd) has been shown to consistently reduce the activity of 
mammalian collagenase and other matrix metalloproteinases 
in the tissues of the periodontium. A recent study on 19 
periodontal patients scheduled for flap surgery demonstrated 
that short term therapy with SDD alone reduced levels of 
proteolytic enzymes, while low dose flurbiprofen alone had 
no significant effect; combined medication with both agents 
resulted in statistically significant synergistic reduction in 
collagenase, gelatinase, serpinolytic activities and to a lesser 
extent, elastase activity [62]. Previous animal studies suggest 
a mechanism whereby NSAIDs contribute to increased up-
take of the tetracycline compound in inflammatory tissue, 
resulting in a synergistic effect and enhanced therapeutic 
impact. Other studies reinforce the efficacy of subantimicro-
bial dosing with doxycycline [63] in smokers and non-
smokers compared with root surface debridement alone in 
significantly reducing periodontal disease parameters [64]. 
  An increase in MMPs associated with equine recurrent 
airway obstruction was effectively inhibited by chemically 
modified tetracyclines, particularly CMT-3, being signifi-
cantly more effective than biphosphonates against some pro-
teases [65]. Definitive MMP inhibitors have potential value 
in overcoming excessive tissue destruction associated with 
proteinases in chronic lung disease and the advantage of hav-
ing minimal side effects over other agents. Acute respiratory 
distress syndrome can be the cause of death in cases of mul-
tiple organ failure. A chemically modified tetracycline was 
shown to inhibit the development of acute respiratory dis-
tress and also prevent septic shock in a slow onset porcine 
model by inhibiting numerous inflammatory mediators [66]. 
These actions have clinical applications in curbing an over-
exuberant inflammatory response in the pathogenesis of 
periodontal diseases.  
CARDIOPROTECTIVE EFFECTS OF TETRACY-
CLINES 
  In a murine model administration of 4mg/kg tetracycline 
dramatically reduced the size of infarct area in a murine 
heart analysed by tetrazolium staining [67]. Translational 
inhibition in mitochondria resulting in cold stress associated 
molecules may be a cardioprotective effect of tetracyclines. 
A subclinical dose of tetracycline is likely to protect the 
heart from ischemic injury and be of therapeutic value in 
suppressing the onset of infarction caused by myocardial 
ischaemia [67]; this demonstrates another application for 
subclinical dosing with tetracycline, also used in the adjunc-
tive management of periodontal disease of potential value in 
those presenting with coexisting cardiovascular disease . 
  Myocardial ischaemia is associated with the activation of 
MMPs and the serine proteinase plasmin. In a rat model, pre-
treatment with Doxycycline has been shown to reduce myo-
cardial infarct size by 37% [68]. Doxycycline inhibits the 
serine protease plasmin while treatment with a broad spec-
trum MMP inhibitor had no effect. Inhibition of plasmin by 
doxycycline may reduce myocyte death and contribute to 
cardioprotection. The effects of timing of this intervention 
was investigated in a rat myocardial infarct model in com-
parison with methyl prednisolone and an aqueous vehicle at 
early (24h) and late (2-7days) post-myocardial infarction 
[69]. The doxycycline group had an improved outcome for 
myocardial recovery compared with methyl prednisolone. 
Inhibition of the serine protease plasmin appears to have 
therapeutic advantage in myocardial infarct patients. 
WOUND HEALING ACTIONS OF TETRACYCLINES 
  Modulation of basement membrane laminin, MMPs, os-
teoblast and osteoclast functions by tetracyclines contribute 
to its effects on wound healing. The effect of low dose tetra-
cycline on modulation of laminin-5 and its association with 
proliferation of junctional epithelial cells during pocket for-
mation was investigated in 30 patients with chronic perio-
dontal disease. Root surface debridement was performed 
with or without adjunctive low dose doxycycline for its non-
antimicrobial effects [70] and monitored 3 monthly for 
twelve months. Gingival crevicular fluid (GCF) samples 
were collected for analysis of laminin and clinical para-
menters of periodontal disease were recorded. The test group 
of patients with periodontal disease was subjected to com-
plete root surface debridement with 20mg bd of low dose 
tetracycline and compared with the randomly selected con-
trol group who received root surface debridement plus pla-
cebo only. It is relevant that the low dose doxycycline group 
showed a significant reduction in GCF levels of Laminin-5 
gamma 2 chain fragments compared with the placebo group. 
Matrix metallo proteinase mediated fragmentation of 
laminin-5 can contribute to pocket formation by stimulating 
epithelial cell migration. Reducing these levels, could be 
another mechanism whereby low dose doxycycline could 
contribute to resolution of periodontal pockets in the long-
term.  
  Chemically modified tetracyclines are effective in inhib-
iting bone resorption by inhibiting osteoclastic actions and 
inducing apoptosis of osteoclasts, in addition to reducing 
bone resorption by inhibiting matrix metallo proteinases.   
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Recent studies [71] demonstrate that the non-antibiotic ana-
logues CMT-3 and CMT-8 of doxycycline and minocycline 
respectively are potent inhibitors of osteoclastogenesis from 
peripheral blood monocytes in response to macrophage col-
ony stimulating factor and RANK at a concentration of 
250ng/ml. The mechanism is reported to be independent of 
osteoblast osteoclast interactions. Over a 24h period, both 
CMT-3 and CMT-8 also induced apoptosis of mature osteo-
clasts at concentrations of 5-20 μg/ml. Inhibition of osteo-
clastogenesis and induction of osteoclast apoptosis are sig-
nificant actions of CMTs, independent of their matrix metal-
loproteinase inhibitory action or osteoblastic interaction [71].  
  It has been shown that CMT-8 and oestrogen can im-
prove wound healing in ovariectomised rats by changing the 
quality of wound bed collagen with improved expression of 
key molecules in wound healing such as laminin-5 gamma 2-
chain [72]. This illustrates another mechanism whereby non-
antimicrobial tetracyclines can contribute to healing re-
sponses. A randomized, placebo controlled double masked 
study compared the effects of administration of low dose 
doxycycline to periodontal patients with or without associ-
ated flap surgery [73], using clinical parameters, microbial 
and bone markers. Adjunctive low dose doxycycline was 
shown to improve periodontal healing and reduce local bone 
resorption. These findings reinforce results of other workers 
in confirming that tetracyclines and their derivatives have 
potential therapeutic benefits in the management of meta-
bolic diseases affecting bone homeostasis by modulating 
osteoblast and osteoclast activities. A novel finding regard-
ing the inhibition of IL-1 induced IL-6 expression by CMT-
8 in murine osteoblasts at a post-transcriptional level affect-
ing the stability of IL-6 mRNA, provides potential for new 
incentives for therapeutic management of IL-6 mediated 
metabolic bone diseases [74].  
ANTI-APOPTOTIC ACTIONS OF TETRACYCLINES 
  Several studies demonstrate anti-apoptotic and anti-
inflammatory effects of minocycline in the context of neuro- 
protection [75-78] and in a lung epithelial cell model [79]. In 
the murine lung alveolar epithelial cell model [79] treated 
with cytomix (TNF-, IL-1, IFN-gamma each at 5ng/ml), 
doxycycline was effective in reducing the formation of nitric 
oxide (NO) from inducible nitric oxide synthase (iNOS), by 
reducing the expression of p38 MAPK resulting in destabili-
zation of iNOS mRNA. In a rat model marked inflammation 
was induced in the striatum by injecting quinolinic acid re-
sulting in enhanced expression of iNOS and cyclooxy-
genase-2 [78]. These responses were reduced with admini-
stration of either minocycline or pyruvate an end product of 
glycolysis which could direct metabolism along a less dam-
aging protective pathway; combined administration of both 
agents resulted in significant attenuation of the inflammatory 
response compared with either agent alone. This has implica-
tions on a therapeutic approach for neurodegenerative disor-
ders with excitotoxic insults and may also have applications 
for other diseases which manifest oxidative stress induced 
tissue damage such as periodontal disease, diabetes and car-
diovascular diseases. 
  When cell free assays of rat brain homogenate were done 
to test the antioxidant potency of minocycline it demon-
strated direct antioxidant effects with radical scavenging 
activity comparable with -tocopherol, a synthetic, racemic 
vitamin E [75]. The radical scavenging actions of mino-
cycline are consistent with its multi-substituted phenol ring 
similar to that of vitamin E, belonging to the class of pheno-
lic antioxidants; they are effective in scavenging free radicals 
resulting in the formation of phenol derived free radicals 
which are relatively stable and non-reactive. Minocycline 
was found to be far more potent than tetracycline in its radi-
cal scavenging potency and inhibition of lipid peroxidation 
by 316- and 200-fold respectively. Minocycline HCl has 
been shown to be very effective in quenching H2O2 levels; 
relative rates of various ROS related processes could con-
tribute to a combination of quenching and scavenging of 
ROS by tetracyclines [80]. These actions of minocycline 
could explain its potency in reducing the parameters of 
periodontal disease progression during adjunctive usage and 
cardioprotection in reducing the size of myocardial infarcts 
[68].  
  ROS are implicated in periodontal tissue damage seen 
during the progression of inflammatory periodontal diseases. 
A net damaging outcome is likely to be seen with an imbal-
ance in oxidant /antioxidant activity due to inadequate pro-
tection from antioxidants such as glutathione. A study on 
periodontal patients demonstrated that resolution of perio-
dontal disease parameters resulted in a significant decrease 
in lipid peroxidation and an increase in salivary glutathione 
levels [81]. Products of lipid peroxidation contribute to 
periodontal disease progression. Accumulation of lipid per-
oxidase products leading to raised levels of oxidative stress 
and imbalance of endogenous antioxidant defence at in-
flammatory sites, has been reported in periodontal patients 
by other workers [82, 83]. ROS activity has been shown to 
be significantly greater in chronic periodontitis than in non-
periodontitis subjects [84]. In this context the antioxidant 
and radical scavenging properties of minocycline are particu-
larly relevant in the adjunctive management of periodontal 
diseases with or without additional inflammatory burden 
from co-existing systemic diseases.  
SUMMARY AND CONCLUSIONS 
  Periodontal patients often present with multiple medica-
tion for DM, CVD arthritis and other systemic diseases. The 
presence of a significant inflammatory burden is a common 
feature driving these conditions with therapeutic applications 
for using adjunctive tetracyclines in a non anti-microbial 
capacity. These actions of tetracyclines encompassing matrix 
metalloproteinase inhibition, antioxidant and anabolic effects 
have been addressed in addition to their antimicrobial appli-
cations in the adjunctive management of periodontal dis-
eases. Some of the positive outcomes of periodontal healing 
in response to tetracyclines as antimicrobial adjuncts could 
be attributed to their anti-inflammatory, antioxidant and ma-
trix stimulatory actions. For instance a study on periodontal 
patients with Type 1 diabetes mellitus demonstrated that 
adjunctive topical application of doxycycline hyclate in addi-
tion to root surface debridement resulted in statistically sig-
nificant improvement in parameters of periodontal healing at 
12 months [85].  
  In a rat model of induced periodontal disease using gin-
gival LPS injections, elevated levels of collagenase (MMP-
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overcome by using a synergistic combination of sub-optimal 
doses of the chemically modified tetracycline CMT-8 and a 
biphosphonate, clodronate [86]; when sub-optimal doses of 
these agents were used individually, there were negligible 
effects on the above parameters. This synergy has therapeu-
tic potential in preventing periodontal tissue damage in pa-
tients with metabolic and other inflammatory diseases such 
as arthritis. The pathophysiology of periodontal diseases and 
arthritis is similar [87]; the confounding effects of medica-
tion has made it difficult to establish a clear link. In a recent 
study of adjuvant induced arthritis in a rat model, arthritic 
changes were associated with raised levels of MMPs, IL-1 
and TNF- in joint tissue; this was ameliorated after TIMP-4 
gene therapy in the treated group compared with the un-
treated control animals [88]. These findings confirm the 
relevance of an over-exuberant inflammatory response in the 
pathogenesis of arthritis, in common with periodontal and 
metabolic diseases; reinforcing the non-antimicrobial thera-
peutic role of tetracyclines in controlling an excessive in-
flammatory burden in view of their MMP inhibitory actions.  
  Adjunctive use of tetracyclines for their non-antimicro- 
bial effects can aid in overcoming the secondary effects of 
diabetes, dyslipidaemia and cardiovascular diseases in perio-
dontal patients, particularly those who smoke. Reduction in 
the parameters of oxidative stress contribute to reduced in-
flammatory burden; this can contribute towards minimising 
the likelihood of overt clinical presentation of these diseases 
in subclinical cases or act in a therapeutic capacity in those 
with overt disease. Specific mechanisms of action of this 
group of drugs has been discussed.  
  It is relevant that other agents with anti-inflammatory, 
antioxidant and pro-anabolic effects have been identified 
over the last decade and shown promise in controlling over-
exuberant inflammatory responses with associated oxidative 
stress induced tissue damage applicable to the disease enti-
ties discussed. Macrophages activated by bacterial compo-
nents release ROS and reactive nitrogen species (RNS), a 
critical part of defence mechanisms. Grape seed proantho-
cyanidins demonstrate a spectrum of actions against oxida-
tive stress. The effect of this compound on murine macro-
phages stimulated with lipopolysaccharides derived from 
periodontopathogens showed significant reduction in NO, 
ROS production and inducible nitric oxide synthase expres-
sion [89], demonstrating strong antioxidant properties of 
proanthocyanidins with potential therapeutic applications for 
periodontal and other inflammatory diseases. An investiga-
tion of the relationship between serum levels of the antioxi-
dant lycopene, linked to monthly tomato consumption and 
congestive cardiac failure in periodontitis patients, showed a 
significant positive correlation between serum lycopene lev-
els and cardioprotection; with an inverse relationship be-
tween serum lycopene and C-reactive protein [90].  
  Recently Ginkgo biloba (Gb) extracts have been shown 
to have antioxidant and anti-inflammatory properties in re-
ducing ROS levels. They consist of flavonoids and terpe-
noids. EGb 761, a standard extract of Gb was used on the 
model Caenorhabditis elegans when subjected to thermal 
stress. There was attenuation of ROS accumulation in re-
sponse to the Gb extract, reduction in the transcription of 
stress inducible catalase genes and glutathione S-transferase 
4, demonstrating its ability to combat oxidative stress [91]. 
In another study, mercury toxicity induced in a rat model 
demonstrated oxidative stress with raised levels of 
malondialdehyde, myeloperoxidase and reduced levels of 
glutathione in multiple organs. In the animals treated with 
Gb extract there was significant reversal in levels of the 
above markers of oxidative stress confirming the antioxidant 
effects of Gb [92].  
  In a diabetogenic cell culture model, we have demon-
strated the antioxidant efficacy of glutathione and insulin 
like growth factor in overcoming oxidative stress induced 
effects of glucose, AGE and nicotine [93]. The antioxidants 
co-enzyme Q10, phytoestrogens and Pycnogenol derived 
from French maritime pine bark have demonstrated effective 
amelioration of oxidative stress in a cell culture model appli-
cable to periodontal disease in smokers [94]. These studies 
highlight the importance of oxidative stress induced disease 
mechanisms and the relevance of combating the damaging 
effects of reactive oxygen species for effective control of 
periodontal and systemic diseases.  
  The anti-inflammatory effects of the established antioxi-
dant agents described above in the context of periodontal and 
metabolic diseases have potential for therapeutic use with 
non-antimicrobial formulations of tetracyclines in subopti-
mal doses to minimise side effects. The non-antimicrobial 
actions of tetracyclines have shown remarkably similar 
mechanisms to those of agents with established anti-
inflammatory / antioxidant potential. These findings clarify 
the multi-faceted actions of tetracyclines which are unique 
amongst antimicrobials, with therapeutic applications in 
periodontal and metabolic diseases.  
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